Covid-19: What now for remdesivir?

  title={Covid-19: What now for remdesivir?},
  author={J. Hsu},
  • J. Hsu
  • Published 19 November 2020
  • Medicine
  • BMJ
The spectre of past pandemics looms large over remdesivir, one of the first drug treatments for covid-19. With a WHO trial finding little benefit, Jeremy Hsu asks if the expensive drug is just Tamiflu redux? 
Major Update: Remdesivir for Adults With COVID-19
This first update of a living rapid review used to inform American College of Physicians Practice Points includes information from a newly published large multinational randomized controlled trial (RCT) as well as the final results of an RCT previously published as a preliminary report.
Covid-19: UK launches antivirals taskforce to deliver home treatments by autumn
Can the UK vaccine taskforce’s success in delivering safe and effective covid vaccines be repeated with new antiviral drugs? Elisabeth Mahase looks at the research pipeline
Covid-19: The lost lessons of Tamiflu
The history of the covid-19 pandemic will be strewn not only with lost lives and livelihoods but with the bloated carcasses of treatments hyped and bought at great expense, only to be found wanting.
The search for antivirals for covid-19
Antivirals are one of the most sought after, yet missing, tools to control SARS-COV-2. Chris Stokel-Walker asks what was learnt from a similar search nearly 20 years ago
Future developments in the prevention, diagnosis and treatment of COVID-19
Remdesivir: Quo vadis?
The global governance of pandemics
The recent history of efforts to cope with crossborder health threats that set the stage for responses to the current pandemic are considered, and the record of international cooperation in the face of COVID19 is reviewed.
Targeted Drug Repurposing Against the SARS-CoV-2 E channel Identifies Blockers With in vitro Antiviral Activity
This study searched for blockers of its E protein viro-porin, an ion channel in the virus to expand the treatment arsenal against COVID-19 and validate the approach and potentially augment the anti-COVID tool kit.
COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development
  • Ramandeep Singh, A. Kang, +4 authors Z. Xing
  • Medicine
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2021
A comprehensive overview to conceptually thread together the latest information on global epidemiology and mitigation strategies, clinical features, viral pathogenesis and immune responses, and the current state of vaccine development is provided.
Overriding drug and medical technology patents for pandemic recovery: a legitimate move for high-income countries, too
Law Centre for Health and Life, Faculty of Law, University of Amsterdam, Amsterdam, The Netherlands WHO Collaborating Centre for Governance, Accountability, and Transparency in the Pharmaceutical


Efficacy of Remdesivir in COVID-19.
The coronavirus disease 2019 (COVID-19) pandemic has strained health care systems across the globe, necessitating drastic public health measures and prompting a series of measures to protect against future pandemics.
Covid-19: Remdesivir has little or no impact on survival, WHO trial shows
The largest trial to date of treatments repurposed for use in the covid-19 pandemic has shown that none of the four drugs studied produced any measurable benefit in mortality or disease course. This
Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19
An overview of remdesivir’s discovery, mechanism of action, and the current studies exploring its clinical effectiveness is provided.
The journey of remdesivir: from Ebola to COVID-19
Overall, current data are insufficient to judge the efficacy of remdesivir for COVID-19, and the results of additional randomized studies are eagerly anticipated.
Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
It is argued that GS-441524 is superior to remdesivir for Covid-19 treatment because of its synthetic simplicity and in vivo efficacy in the veterinary setting.
Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
These Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay.
FDA approves remdesivir, first treatment for COVID‐19
  • 2020
FDA approves remdesivir, first treatment for COVID-19 In October, the U.S. Food and Drug Administration approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12
WHO downgrades status of oseltamivir
  • M. Ebell
  • Medicine
    British Medical Journal
  • 2017
Important lessons from the Tamiflu story are learned about what can be done to prevent norovirus infection and what should be done in the event of a pandemic.
The Tamiflu fiasco and lessons learnt
This article takes a comprehensive relook on the Tamiflu saga, and suggests some ways and means to avoid a similar situation in the future.